Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease
Read more
30
June 2023
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
Read more
16
June 2023
Enterome selected for the prestigious French Tech 2030 program designed to champion breakthrough technological innovations in France
Read more
14
June 2023
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
Read more
31
May 2023
Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO
Read more
09
May 2023
Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors
Read more
10
March 2023
Enterome’s Management to Attend Upcoming Meetings
Read more
12
December 2022
Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma
Read more
07
December 2022
Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022
EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study
W. Wick, et al.
2022 ESMO Immuno-Oncology Congress
Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab
W. Wick, et al.
2022 ESMO Immuno-Oncology Congress
EO2401 therapeutic vaccine for patients with recurrent glioblastoma Phase 1/2 ROSALIE study
D. Reardon, et al.
2022 SNO Annual Meeting
Strong immune response to therapeutic vaccination EO2401 microbiome-derived vaccine + nivolumab – Interim report of the EOGBM1-18/ROSALIE study
A. Maia, et al.
2022 SITC Annual Meeting
EO2401 microbiome derived therapeutic vaccine + nivolumab, with/without standard continuous, or low-dose symptom directed, bevacizumab, in recurrent glioblastoma: phase 1-2 EOGBM1-18/ROSALIE study
D. Reardon, et al.
2022 SITC Annual Meeting
EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study
A. Idbaih, et al.
2022 EANO Meeting
EO2401 therapeutic vaccine for patients with adrenocortical carcinoma (ACC): Phase 1/2 SPENCER study (NCT04187404)
E. Baudin, et al.
2022 ESMO Annual Meeting
Relevant Literature
*authored by Enterome
OncoMimics approach
Drug discovery in the age of deep sequencing
C. Bonny
MedNous, May 2022
A very high level of crossreactivity is an essential feature of the T-cell receptor
D. Mason
Immunology today, September 1998
Cross-reactivity of T cells and its role in the immune system
G. Petrova, et al.
Crit Rev Immunol., March 2012
Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire
V. l. Zarnitsyna, et al.
Front Immunology, December 2013
Why must T cells be cross-reactive?
A. Sewell, et al.
Nature Reviews Immunology, August 2012
Challenges in the development of effective peptide vaccines for cancer
C. Buteau, et al.
Mayo Clin Proc, April 2002
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
M. Sioud, et al.
Scandinavian journal of immunology, January 2018
Pre-existing heterologous T-cell immunity and neoantigen immunogenicity
Q. Leng, et al.
Clin Transl Immunology, March 2020
Effector and Memory T cell Responses to Commensal Bacteria
Y. Belkaid, et al.
Trends Immunology, June 2013
EndoMimics approach
Bacterial Protein Mimetic of Peptide Hormone as a New Class of Protein- based Drugs
S. Fetissov, et al.
Current Medicinal Chemistry, October 2017
Gut microbiota in human metabolic health and disease
Y. Fan, et al.
Nature Reviews Microbiology, September 2020
IL-10 produced by macrophages regulates epithelial integrity in the small intestine
T. Morhardt, et al.
Scientific reports, February 2019
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
W. Ouyang, et al.
Immunity, April 2019
Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease
Tomaro-Duchesneau, et al.
Scientific Reports, March 2020
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Yoon, et al.
Nature Microbiology, April 2021
Mapping interactions of microbial metabolites with human G-protein-coupled receptors
Colosimo, et al.
Cell, Host & Microbe, August 2019
Computational platform
*GeneMark-HM: improving gene prediction in DNA sequences of human microbiome
A. Lomsadze, et al.
NAR Genomics and Bioinformatics, June 2021
*Scalable workflow and reproductible data analysis for genomics
F. Strozzi, et al.
Methods in molecular biology, July 2019
*MSP-Miner-abundance-based reconstitution of microbial pan-genomes from shotgun metagenomic data
F. Onate, et al.
Bioinformatics, May 2019
*A unified catalog of 204,938 reference’ genomes from the human gut microbiome
A. Almeida, et al.
Nature biotechnology, July 2020
*Incorporating phylogenetic information in microbiome differential abundance studies has no effect on detection power and FDR control
A. Bichat, et al.
Frontiers in microbiology, April 2020
A metagenomic strategy for harnessing the chemical repertoire of the human microbiome
Sugimoto, et al.
Science, December 2019
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals
Asnicar, et al.
Nature Medicine, January 2021
*Impact of laparoscopic Roux-enY gastric bypass and sleeve gastrectomy on gut microbiota – a metagenomic comparative analysis
W. Farin, et al.
Surgery for obesity and related diseases, March 2020
Focus on inflammatory diseases
*Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation
N. Tchitchek, et al.
JCI Insight, September 2022
*Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease
G. Chevalier, et al.
Microbiome, August 2021
*Antimicrobial resistance profiles of adherent invasive Escherichia coli show increased resistance to B-lactams
M. Martinez-Medina, et al.
Antibiotics, May 2020
*Gut microbiota diversity is reduced in smokers with Crohn’s disease
J. Opstelten, et al.
Inflammatory bowel diseases, September 2016
Focus on the gut microbiome impact on human health
*The human gut microbiome as source of innovation for health: which physiological and therapeutic outcomes could we expect?
J. Doré, et al.
Therapy, February 2017
Downloads
MSPminer
The binary is freely available for non-commercial users
Enterome France
Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Lab facilities
Biocluster Genopole
5 rue Henri Desbruères – 91030 Evry Cedex
